Abstract
Diabetes Mellitus (DM) is a chronic disease that occurs when the pancreas does
not produce enough insulin, or alternatively, when the body cannot effectively
use the insulin it produces.
When China started its economic reform in 1978, the diabetes disease rate was
about 0.6% in the Chinese population. As China entered the rapid growth phase
of its economic development, the diabetes disease rate has arisen rapidly. In
1995, the diabetes disease rate reached 1.5% and in 2000 the diabetic disease
rate was 2.4% with the total number of diabetes patients at 31 million in
China. The average addition of new diabetes patients each year was about 1.5
millions. Due to the increased numbers of diabetes patients and the
improvements of living standards, the market size of diabetes drugs has
increased steadily in China. The market size of diabetes drugs in 2002 was
about RMB 4.187 billion and increased to RMB 7.495 billion in 2007 (USD 1.071
billion at 7:1 USD:RMB exchange rate) with an average annual growth of 13%.
The annual growth rate from 2006 to 2007 was a significant 20.98%.
This report has systemically analyzed the Chinese diabetes drug market. All
drug data are based on hospital drug prescription and drug purchasing data
from the hospital data monitor system that the China Nan Fang Institute of
Medical and Economic Information has developed and maintained (Nan Fang
Institute is a direct subsidiary of the Chinese State Food and Drug
Administration, the SFDA). Sampled hospitals are from major Chinese cities
across different geographic locations, including Beijing, Shanghai, Guangzhou,
Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering
significant percentages of all hospitals in these regions.
Market shares from all major players including multinational and Chinese
pharmaceutical companies and their major diabetes products are analyzed
systemically based on data from significant number of Chinese hospitals. The
comprehensive hospital utilization data of major diabetes drugs will present
you a clear picture of the competition landscape of Chinese diabetes drug
market and the market potential for your company' s product(s) that already
marketed in China or if you are planning to bring your drugs to the China
market.
This China Diabetes Drug Market Report has been a Must-have reference for all
levels of decision makers in pharmaceutical companies, medical device
companies, healthcare investing companies and healthcare consulting companies.
These unique drug prescription and utilization data can provide valuable
information for new product development, marketing and strategic planning
functions for pharmaceutical companies. Compared to expensive customized drug
reports in China, this multi-client report provides significant savings and
great cost/benefit to pharmaceutical companies and interested parties.
| 
View Cart
